hVIVO plc HVO

Sunda Energy PLC (AIM:SNDA, FRA:GHA0) has raised £5.25 million to fund completion of its New Zealand acquisition. It's also launching a retail offer for a further £525,000. Meridian Mining Plc (LSE:MNO, TSX:MNO, OTCQX:MRRDF) has delivered a net present value of $2.09 billion for its Cabaçal project in Brazil. The CEO says the economics could make it the next major near-term gold-copper mine. Quantum Helium Ltd (AIM:QHE) is targeting Q4 2026 for a larger fracture stimulation programme at Sagebrush-1 in Colorado. It's also taking a 9% stake in Herencia Resources. Light Science Technologies Holdi

Pan African Resources PLC (LSE:PAF, OTCQX:PAFRY, JSE:PAN) has reported record production and earnings for FY2026 after a 40% jump in output. It's now moved from net debt to a "really healthy cash balance." CEO Cobus Loots says its 2027 production target is not a massive stretch. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has delivered a sixth straight year of growth, with profit up 24%. CFO Kris Hampson says the group is well positioned, with a very healthy order book. IP Group PLC (LSE:IPO) has made a strong start to 2026, with NAV per share reaching around 117p. Cash proceeds have alread

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the company's results for the first half of 2026, its record order book, full-year guidance and the expansion of its clinical research services. Khan said hVIVO generated around £16.3 million in revenue in H1, alongside an EBITDA loss of £4.5 million, ending the period with £13 million in cash, a performance in line with the company's previous guidance that 2026 would be weighted towards the second half. A key focus was the order book. Three sizeable human challenge trial contracts, including hVIVO

Chesnara PLC (LSE:CSN) saw operating capital generation jump 79% to £96 million in the first half.  CEO Steve Murray also highlighted the group's 185% solvency coverage ratio and an active acquisition pipeline. Solvonis Therapeutics PLC (LSE:SVNS, OTC:SLVNF) has raised £1.3 million to push forward its CNS drug pipeline.  That includes trials for alcohol use disorder and addiction treatments. hVIVO PLC (AIM:HVO) has bought CRS Berlin to expand into dermatology and women's health trials.  The CEO says it opens up new markets and cross-selling opportunities in Germany. Gelion PLC (AIM:GELN, OTC:G

hVIVO PLC (AIM:HVO) has bought a Berlin clinical research unit for just €250,000 upfront. Most of the price is tied to future revenue, keeping the deal self-funding. Rome Resources Plc (AIM:RMR) has returned strong tin and tungsten results from its New Brunswick exploration in Canada. Trenching starts in September, with a possible drill campaign lined up for 2027. Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) called Q2 its "best quarter yet," with adjusted EBITDA up 300% year on year. Revenue more than doubled thanks to growth in Colombia's Tapir block. Bradda Head Lithium Ltd (AIM:BH

London, UK – 27 August 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces the acquisition of CRS Clinical Research Services Berlin GmbH ("CRS Berlin"). Highlights Acquisition of a specialist Phase I/II clinical research unit with an established revenue base, multiple pharma relationships, a strong orderbook and proven track record with 350 studies completed to dateExpected to be immediatel

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan spoke with Proactive's Stephen Gunnion about the acquisition of CRS Berlin and how the clinical trial unit will expand hVIVO's early drug development platform, therapeutic expertise and presence in Germany. CRS Berlin is a Phase I and Phase II clinical trial unit with experience across more than 300 trials, with particular strength in dermatology and women's health and a track record working with biotech and mid-sized pharma companies. The business brings an order book of just under €10 million and is expected to be earnings accretive for ful

hVIVO PLC (AIM: HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's latest trading update, highlighting a record order book of more than £65 million that supports expectations for a much stronger second half of 2026. Khan explained why first-half revenue of around £16.3 million and an adjusted EBITDA loss were always expected, with contract wins weighted towards the second half of the year. He said one of the company's strongest-ever periods of new business, following the launch of its integrated clinical development platform, has extended revenue visibility in

Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that Chief Executive Officer Rick Pierce will speak at the Capital Markets Day hosted by hVIVO plc (AIM: HVO) on June 11, 2026 in Canary Wharf, London.

Decoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the execution of a strategic development initiative designed to support the advancement of the company's Designable Multi-Antiviral (D-MAV) candidates into Phase 1 first-in-human and Phase 2a human proof-of-concept studies.

S&U PLC (LSE:SUS) has reported first-quarter trading ahead of budget and the prior year, with its motor finance arm Advantage Finance seeing transactions jump 63% year-on-year. The company is confident of achieving double-digit growth this year, with a securitisation project set to deliver lower-cost medium-term funding. 88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) says its Augusta-1 well in Alaska remains on track for a Q1 2027 spud, targeting up to 133.7 million barrels of gross unrisked resources across three stacked reservoir intervals. A farm-out process is underway, with multip

hVIVO PLC (AIM:HVO) has landed its third human challenge trial contract in recent months, this time with a European biotech client for an influenza study starting almost immediately. CEO Mo Khan says the company is now signing full clinical trial agreements rather than earlier-stage deals, reducing cancellation risk and bringing revenue recognition forward. Bango PLC (AIM:BGO, OTCQX:BGOPF) has added LinkedIn to its Digital Vending Machine platform, giving telcos, banks and retailers a new way to bundle LinkedIn Premium alongside other subscription services. CEO Paul Larbey says the deal reflec

hVIVO PLC (AIM:HVO) chief executive Yamin 'Mo' Khan tells Proactive's Stephen Gunnion that the company has secured its third human challenge trial contract in recent months, this time with a new European biotech client for an influenza study starting almost immediately. Khan describes a "significant uptick" in pipeline opportunities and contract conversions, a marked improvement on the slowdown seen in 2025. Crucially, hVIVO is now signing full clinical trial agreements rather than earlier-stage deals, reducing cancellation risk and bringing revenue recognition forward. The company has strong

hVIVO PLC (AIM:HVO) has signed its largest-ever human challenge trial contract, testing a whooping cough vaccine for US biotech ILiAD Biotechnologies. The trial will involve more than 500 volunteers and is expected to generate the majority of its revenue across 2026 and 2027. Rift Helium PLC (AIM:RIFT) made a strong debut on AIM, with shares opening 10% above the 10p issue price after raising £8.1 million. The Tanzania-focused explorer is targeting a 19 billion cubic foot helium resource and plans to drill within the next 12 months. Galliford Try Holdings PLC (LSE:GFRD, FRA:3WC) has secured a

Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) has cleared its final regulatory hurdle, with full MHRA approval secured for its TOPICAL trial across six UK sites. Interim data on its CRS therapy is expected this summer, with US payer research pointing to a big opportunity. Arecor Therapeutics PLC (AIM:AREC) is advancing its lead insulin candidate AT278, which it says outperforms best-in-class rivals for use in insulin pumps. A Phase 2 trial is targeted for the second half of 2026, backed by a partnership with Sequel Med Tech. hVIVO PLC (AIM:HVO) beat EBITDA guidance in 2025 and closed the

hVIVO PLC (AIM:HVO) CEO Yamin 'Mo' Khan joined Proactive's Stephen Gunnion to discuss the company's full-year 2025 results, which showed financial resilience despite a tough macro environment. Revenue came in at just under £47 million, in line with expectations, while EBITDA of just over £1 million beat earlier guidance of a small loss, driven by strong cost discipline, cancellation fees, and a solid Q4. The company closed the year with over £14 million in cash. Strategically, hVIVO made meaningful progress on diversification. Acquisitions, including clinical trial units in Germany and UK-base

hVIVO PLC (AIM:HVO) has signed a deal with Traws Pharma to run an influenza human challenge trial in London. The contract coincides with a rebrand, bringing all its services under one roof. Connecting Excellence Group PLC (AQSE:XCE, OTCQB:XCELF) has been paid in Bitcoin for recruitment services, a first for a UK-listed recruiter. The payment of 0.516 BTC takes its total treasury holdings to just under 53 Bitcoin. ACG Metals Ltd (LSE:ACG, OTC:ACGAF) posted adjusted EBITDA of $76.3 million for 2025, with its Gediktepe mine in Turkey delivering strong margins. A transition to copper and zinc conc

hVIVO PLC (AIM:HVO) chief scientific officer Dr Andrew Catchpole talked with Proactive's Stephen Gunnion about a newly signed contract with Traws to conduct an influenza human challenge trial, designed to evaluate a prophylactic antiviral drug. Dr Catchpole explained that the study will use one of hVIVO’s recently developed influenza challenge models, which deliver “really robust infection rates and really good disease profiles, ideal for testing antiviral candidates.” The trial will involve 150 participants, reflecting a broader industry trend toward larger, more data-rich human challenge tri

hVIVO PLC (AIM:HVO) chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company securing a landmark contract to deliver the world’s first pivotal Phase III human challenge trial for ILiAD’s whooping cough vaccine candidate. Khan explained that the agreement marks a major milestone for hVIVO, representing the largest contract in the company’s history and involving the highest number of clinical participants it has ever managed. He highlighted the broader implications for patients, noting that human challenge trials can significantly accelerate the path to market fo

hVIVO is back in focus after analysts reaffirmed a £0.18 per share price target, with fresh research updating the narrative around what underpins that figure. The latest commentary suggests this target is now supported by revised assumptions from more bullish voices, reflecting how they currently view the company’s setup. As you read on, you will see how both optimistic and cautious analysts are framing this £0.18 target and what that might mean for following the evolving story. Analyst Price...